Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model

Kasper Almholt, Anna Juncker-Jensen, Ole Didrik Lærum, Keld Danø, Morten Johnsen, Leif Røge Lund and John Rømer
Kasper Almholt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Juncker-Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ole Didrik Lærum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keld Danø
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morten Johnsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leif Røge Lund
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Rømer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0251 Published September 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Galardin/GM6001/Ilomastat.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Primary tumor growth and metastasis in Galardin-treated mice. Tumor size was monitored weekly by palpation in FVB-PymT mice that were randomly distributed to receive the MMP inhibitor Galardin (n = 26), placebo (n = 26), or no treatment at all (n = 27). Treatment was started at age 41 to 45 d by s.c. insertion of 60-d slow-release tablets containing 150 mg Galardin or placebo. The tablets were left in place until the mice were killed at age 92 to 96 d and analyzed for lung metastasis. The lengths (l) and widths (w) of every tumor in each mouse was used to estimate the total tumor volume: V = ∑(lw2π / 6) as described (22). A, geometric mean of tumor volumes plotted versus age for untreated (○), placebo-treated (▵), and Galardin-treated (▴) mice. B, tumor volumes at sacrifice. Columns, geometric means; bars, 95% confidence interval. C, total metastasis volume was quantified with an unbiased stereologic technique (30) on five to eight evenly spaced H&E-stained sections of the lungs from each mouse. Columns, medians; bars, 95% confidence interval.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Increased MMP-2 activity in Galardin-treated tumors. Gelatin zymography of tumor extracts from placebo- and Galardin-treated tumors. The levels of pro-MMP-2 and active MMP-2 are increased in Galardin-treated tumors. Pro-MMP-9 is seen sporadically in tumors from both groups.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Collagen deposition in healthy mammary glands and Galardin-treated mammary tumors. The no. 4 (right side) mammary glands were obtained from 92- to 96-day-old FVB-PymT mice that had been randomly distributed to receive the MMP inhibitor Galardin or placebo starting at age 41 to 45 d. The no. 4 mammary gland was also obtained from tumor-free nontransgenic mice matched for strain and age. Sections of the tissue samples were stained with PicroSirius Red to label collagen type I (yellow to red) and III (green) under polarizing microscopy. Sections were counterstained with Weigert's hematoxylin (black nuclei). A and B, no. 4 mammary gland of a tumor-free nontransgenic mouse under bright-field (A) and polarized (B) illumination for comparison. C, C′, C″, representative tumors from placebo-treated mice. D, D′, D″, representative tumors from Galardin-treated mice. The collagen-rich skin is visible in several panels. Bar, 500 μm.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Histopathologic progression of Galardin-treated tumors. The no. 4 (right side) mammary glands were obtained from 92- to 96-day-old FVB-PymT mice that had been randomly distributed to receive the MMP inhibitor Galardin (n = 26), placebo (n = 26), or no treatment at all (n = 27), starting at age 41 to 45 d. H&E-stained sections of the tissue samples were scored according to the following defined histopathologic stages (25, 33): normal gland (A), hyperplasia (B), adenoma (C), early carcinoma (D), or late carcinoma (E). Data are presented as superimposed histogram traces indicating the percentage of tissue samples that received tumor grade scores A to E for each of the three groups of mice: untreated (○), placebo-treated (▵), and Galardin-treated (▴). The observed distribution differences were not significant (Kruskal-Wallis test, P = 0.13).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Expression of MMP-7, -9, and -10 mRNA in MMTV-PymT-induced mammary cancers and lung metastases. MMP mRNAs were detected by in situ hybridization in primary tumors (A-C) and lung metastases (D) with antisense RNA probes. Expression is seen as silver grains in the bright-field images (row 1) and white reflections in the dark-field images (row 2). Hybridization with a nonoverlapping antisense RNA probe (row 3) and the corresponding sense RNA probe (row 4) on adjacent sections provided positive and negative controls. A, MMP-10 mRNA was infrequent in the primary breast tumors but was occasionally detected quite prominently in narrow bands of connective tissue in areas of compact tumor tissue (arrows). B, MMP-7 mRNA was practically absent in the primary breast tumors and was restricted to occasional cancer cells (arrows) adjacent to necrotic areas (n). C, MMP-9 mRNA was practically absent in the primary breast tumors but was found in scattered stromal cells (arrows) near or adjacent to necrotic areas. D, MMP-9 mRNA was present in scattered cells throughout the entire lung tissue but was not convincingly associated with lung metastases (compare rows 2 and 3 with row 4). Sections were counterstained with H&E. Bars, 100 μm (A and D), 50 μm (C), and 25 μm (B).

Tables

  • Figures
  • Table 1.

    Galardin treatment of MMTV-PymT transgenic mice

    Treatment group
    UntreatedPlaceboGalardin
    No. mice272626
    Age at sacrifice (d)94.1 ± 193.8 ± 194.4 ± 1
    Tumor incidence at sacrifice (%)100100100
    Final primary tumor volume (geometric mean; cm3)*3.373.291.69
    Final primary tumor volume (95% confidence interval of the geometric mean; cm3)2.50-4.562.45-4.411.28-2.23
    Dissemination to lymph nodes, brachial + axillary (incidence; %)†30 (31/105)29 (30/102)21 (22/103)
    Dissemination to brachial lymph nodes (incidence; %)†25 (13/52)29 (15/51)22 (11/51)
    Dissemination to axillary lymph nodes (incidence; %)†34 (18/53)29 (15/51)21 (11/52)
    Lung metastasis (incidence; %)‡100 (27/27)92 (24/26)58 (15/26)
    Lung metastasis volume (median; mm3)§1.390.560.0030
    Lung metastasis volume (95% confidence interval of the median; mm3)0.23-3.050.19-2.340-0.048
    Lung metastasis volume (geometric mean; mm3)∥0.920.260.0033
    • NOTE: A cohort of FVB-PymT mice were either left untreated or implanted with placebo or Galardin pellets and monitored weekly for tumor onset and killed at age 92 to 96 d. Primary tumor volume and tumor dissemination to regional lymph nodes and to lungs were assessed at the time of sacrifice.

    • ↵* t test on log-transformed data (placebo versus Galardin): P = 0.0014.

    • ↵† Not significant.

    • ↵‡ Fisher's exact test (placebo versus Galardin): P = 0.009.

    • ↵§ Mann-Whitney U test (placebo versus Galardin): P < 0.0001.

    • ↵∥ The geometric mean is also reported for direct comparison with earlier work (22, 23). To allow logarithmic transformation, metastasis volumes of zero were assigned a value of 10-4 mm3. t test on log-transformed data (placebo versus Galardin): P < 0.0001.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (9)
September 2008
Volume 7, Issue 9
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model
Kasper Almholt, Anna Juncker-Jensen, Ole Didrik Lærum, Keld Danø, Morten Johnsen, Leif Røge Lund and John Rømer
Mol Cancer Ther September 1 2008 (7) (9) 2758-2767; DOI: 10.1158/1535-7163.MCT-08-0251

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model
Kasper Almholt, Anna Juncker-Jensen, Ole Didrik Lærum, Keld Danø, Morten Johnsen, Leif Røge Lund and John Rømer
Mol Cancer Ther September 1 2008 (7) (9) 2758-2767; DOI: 10.1158/1535-7163.MCT-08-0251
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
  • Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement